background image

News & Media

Press Release

MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference

NEW YORK, Dec. 1, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company’s management team will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference. Canaccord Genuity New […]

Read More